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Conformational transitions of the cellular form of the
prion protein, PrPC, into an infectious isoform, PrPSc,
are considered to be central events in the progres-
sion of fatal neurodegenerative diseases known as
transmissible spongiform encephalopathies. Tricy-
clic phenothiazine compounds exhibit antiprion
activity; however, the underlying molecular mecha-
nism of PrPSc inhibition remains elusive. We report
the molecular structures of two phenothiazine com-
pounds, promazine and chlorpromazine bound to a
binding pocket formed at the intersection of the
structured and the unstructured domains of the
mouse prion protein. Promazine binding induces
structural rearrangement of the unstructured region
proximal to b1, through the formation of a ‘‘hydro-
phobic anchor.’’ We demonstrate that these mole-
cules, promazine in particular, allosterically stabilize
the misfolding initiator-motifs such as the C terminus
of a2, the a2-a3 loop, as well as the polymorphic b2-
a2 loop. Hence, the stabilization effects of the pheno-
thiazine derivatives on initiator-motifs induce a PrPC
isoform that potentially resists oligomerization.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs), also known
as prion diseases, affect humans and a variety of mammalian
species (Aguzzi and Polymenidou, 2004). These diseases are
progressive, degenerative disorders of the CNS that result in
dementia, significant motor dysfunction, and ultimately lead to
death (Collinge, 2001). Human prion diseases exhibit highly
heterogeneous clinical and pathological manifestations (Ri-
chardson and Masters, 1995). The sporadic Creutzfeldt-Jakob
disease (CJD) is the most common form of prion disease in
humans, affecting 1–2 persons per million annually worldwide;
CJD has symptoms of rapidly progressing dementia with a
median survival of 4–6 months (Heinemann et al., 2007). Two
less common human prion diseases are the acquired and the
inherited forms; the acquired form develops in healthy humans
after exposure to contagious agents, whereas genetic mutationsStructure 22, 29in the prion protein gene lead to inherited prion diseases present-
ing with various clinicopathlogical symptoms including classic
CJD, Gerstmann-Straussler-Scheinker (GSS) disease, and fatal
familial insomnia (FFI) (Prusiner, 2001).
The aggregation of a soluble protein into an insoluble, b sheet-
rich amyloid fibril is a defining characteristic of many neuro-
degenerative diseases such as Alzheimer’s, Parkinson’s, and
Huntington’s diseases, including prion disorders (Brundin
et al., 2010). Experimental evidence now suggests a unifying
‘‘prion-like’’ mechanism underlying these diseases; the mis-
folded protein aggregates induce a self-perpetuating process
that leads to amplification and cell-to-cell spreading of the
pathogenic protein assembly. A hallmark of prion disease is
the accumulation of amyloid fibrils in brain tissue, resulting in
excessive neuronal degeneration and spongiosis (Will, 1999).
The conversion of ubiquitously present normal cellular prion pro-
tein (PrPC) into a pathogenic conformation (PrPSc) is a crucial
step for the onset of this disease. PrPC is an extracellular mem-
brane anchored protein that contains a flexible, unstructured
N-terminal domain and a globular C-terminal domain comprising
two short native antiparallel b strands, b1 and b2, and three a
helices, a1, a2, and a3. The pathogenic conformation PrPSc is
polymeric, heterogeneous in terms of quaternary structure, and
enriched in b sheets; PrPSc also possesses abnormal physio-
chemical properties such as protease resistance, insolubility,
and the propensity to polymerize into amyloid-like fibrils. The
transmission of TSE is essentially a PrPSc-dependent phenome-
non; PrPSc acts as a template for self propagation by recruiting
normal cellular PrP molecules in a cyclic fashion, leading to the
formation of amyloid fibrils (Castilla et al., 2005; Sigurdson
et al., 2009).
Currently, there are no therapeutic approaches to prevent or
reverse the progressive and ultimately fatal course of human
prion diseases. A handful of chemical chaperones from various
molecular families, including polyanionic, tricyclic, tetrapyrrolic,
polyene antibiotics, tetracycline, b sheet breaker peptides,
Congo red, and others, have been found to have antiprion prop-
erties in cell culture models of prion disease (Bertsch et al., 2005;
Kocisko et al., 2003). Measurement of PrPSc levels in infected
neuroblastoma cell culture is an efficient protocol for qualitative
and quantitative analysis of antiprion compounds (Solassol et al.,
2003). However, the molecular targets and mechanisms of
action for the active compounds remain unknown. Given the
diverse group of chemical moieties that exhibit antiprion proper-
ties, it is plausible that their modes of action involve different1–303, February 4, 2014 ª2014 Elsevier Ltd All rights reserved 291
Table 1. Data Collection and Refinement Statistics
Complex
POM1Fab:moPrP:
promazine
POM1Fab:moPrP:
chlorpromazine
Data collection
statistics
SSRL APS
Space group C2 C2
Resolution, A˚ 50.0–1.9 (1.97–1.90) 50.0–2.2 (2.28–2.20)
Completeness (%) 98.3 (85.1) 97.3 (86.4)
Rmerge
a 0.09 (0.62) 0.08 (0.57)
I/sI 15.4 (2.0) 14.0 (1.5)
Redundancy 4.1 (3.2) 3.5 (2.2)
Total number of
reflections
213,303 112,455
Unique reflections 52,155 32,491
Cell dimensions
a, b, c (A˚) 83.21, 106.03, 75.73 83.26, 106.88, 75.59
a, b, g () 90, 95.68, 90 90, 95.32, 90
Refinement
Rwork
b 0.21 0.20
Rfree
b 0.24 0.23
Total number of atoms 4,630 4,649
Protein 4,203 4,205
Ligand/Ions 20 21
Water molecules 407 423
Average B-factor (A˚)a 41.33 51.37
Protein 41.29 51.37
Water molecules 45.81 61.21
Rmsd
Bond lengths (A˚) 0.005 0.008
Bond angles () 1.084 1.269
The data in parentheses refer to the reflections in the highest resolution
shell.
aRmerge = ShklSij Ii(hkl)  hI(hkl)ij/ShklSi Ii(hkl), where hI(hkl)i is the mean
intensity for multiply recorded reflections.
bRwork and Rfree = Shkl (jFobsj jFcalj)/Shkl jFobsj, for reflections in the work-
ing and test sets (5% of the data).
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Anti-Prion Mechanism of Phenothiazine Compoundsmolecular targets or unrelated mechanisms. At the molecular
level, rational design of small molecule therapeutics against
prion disease can involve stabilization of PrPC, clearance of
PrPSc, or inhibition of the process of conversion between these
prion protein isoforms. Stabilizing the native fold of PrPC is likely
the most prudent approach, as this may remove substrate from
pathogenesis while preserving normal cellular function.
Among the diverse group of antiprion compounds, tricyclic
molecules like promazine, chlorpromazine, acepromazine, and
quinacrine appear to be promising candidates for immediate
application in the treatment of prion diseases, as these com-
pounds are currently used for the treatment of other ailments
and have well-established safety profiles (Goodman and Gilman,
1970). In two independent studies, incubation of quinacrine
induces clearance of protease-resistant PrPSc, after a persistent
prion infection of neuroblastoma cells (Doh-Ura et al., 2000;
Korth et al., 2001). However, in vivo administration of quinacrine
in human clinical studies resulted in a mixed outcome. In some292 Structure 22, 291–303, February 4, 2014 ª2014 Elsevier Ltd All rpatients, quinacrine treatment improved clinical symptoms tran-
siently, whereas in others, beneficial effects were not observed
(Nakajima et al., 2004). Thus, the positive in vitro effects of PrPSc
inhibitors, as well as the potential efficacy from in vivo studies
(Cronier et al., 2007) suggest that determining the molecular
basis for their mechanism of action will aid in the design of
therapeutic agents against prion and prion-like diseases.
In this study, we present the molecular crystal structure of
the prion protein bound to two phenothiazine compounds,
promazine and chlorpromazine. The role of these molecules in
the stabilization of PrPC was also analyzed using nuclear
magnetic resonance (NMR) spectroscopy and molecular dy-
namics simulations. We show that these antiprion compounds
bind to a well-defined hydrophobic pocket maintained by resi-
dues from helix a2 and the antiparallel b strands, b1 and b2.
We suggest the binding of promazine could stabilize several
PrPCmotifs that have previously been implicated in the transition
of PrPC to a neurotoxic state.
RESULTS
We have determined the molecular structures of promazine
and chlorpromazine bound to the recombinant mouse prion
protein (moPrP) by forming crystals of the ternary complexes
of POM1 Fab:moPrP:promazine and POM1 Fab:moPrP:
chlorpromazine; the structures were solved and refined by
X-ray crystallographic methods to resolutions of 1.9 A˚ and
2.2 A˚, respectively (Table 1). After several unsuccessful attempts
to cocrystallize POM1 Fab:moPrP:compound, we relied on the
soaking the POM1 Fab:moPrP crystals in solutions of the com-
pounds. The POM1 Fab was used as a crystallization aid for
the moPrP (117–230), given that crystallization of the moPrP
alone is difficult with nonreproducible outcomes. Another advan-
tage of using POM1 Fab to facilitate crystallization is that the
binding interface is relatively small, leaving 91% (5,710 A˚2)
of the surface area of moPrP accessible for compound binding
(Baral et al., 2012). The residue numbering scheme presented
here for moPrP is in accordance with that of huPrP.
Phenothiazine Binding Site at the Intersection of b1-b2
and a2
Promazine is bound in a pocket formed by the side chains of
residues on a2, b2, and b1 that lie opposite to the binding epitope
of POM1 Fab (Figure 1A). The tricyclic phenothiazine ring of the
promazine is bent around bonds C1-N-C12 and C6-S-C7 giving
the molecule a butterfly appearance having a dihedral angle of
135 between the aromatic planes (Figure 1A and Figure S1
available online). The dimethylaminopropyl side chain that is
attached to the N-atom of the phenothiazine ring has an approx-
imately ‘‘all staggered’’ conformation and extends above the
convex side of ring. The phenothiazine part of promazine is
bound in a predominantly hydrophobic pocket comprised of
the residues Val122, Leu125, Tyr128, Tyr162, Ile182, Gln186,
Val189, and Thr190, with the tricyclic scaffold stacked between
the side chains of Leu125 on one side and Gln186 on the other
(Figures 1B and 2A). The dimethylaminopropyl side chain pro-
trudes outside the binding pocket while making hydrophobic
contacts with the side chains of Val122 and Tyr162. The 2.2 A˚
crystal structure of POM1 Fab:moPrP:chlorpromazine displaysights reserved
Figure 1. Crystal Structure of POM1 Fab:
moPrP:promazine
(A) The complex of POM1 Fab:moPrP in the
surface representation. POM1 Fab light chain,
heavy chain, and mouse prion protein are colored
orange, brown, and green, respectively. Proma-
zine is shown in the space-filling representation
with carbon, nitrogen, and sulfur atoms colored
cyan, blue, and yellow, respectively. The electron
density is contoured at 0.75 s from a 2jFoj  jFcj
map, promazine is shown as in a ball and stick
representation.
(B) moPrP residues in contact with promazine are
shown as sticks, whereas promazine is shown as a
ball and stick model. The electrostatic surface of
moPrP is oriented to show the hydrophobic bind-
ing pocket, with promazine shown as a ball and
stick model.
See also Figure S1.
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Anti-Prion Mechanism of Phenothiazine Compoundsweak electron density for chlorpromazine, indicating that the
bound chlorpromazine is only partially occupied (Figure S2A).
Chlorpromazine contacts residues Leu125 and Gln186 of
moPrP, these two residues bind promazine from opposite sides
of the tricyclic ring. In the present interpretation, the mode of
binding of chlorpromazine is different from that of promazine,
although both molecules recognize a similar hydrophobic sur-
face region on moPrP.
Structural superposition of the prion protein molecules in the
free (Protein Data Bank [PDB] ID: 4H88) and ligand bound states
have an overall root-mean-square deviation (rmsd) of 0.3 A˚ for
the Ca atoms (residues 125–225), indicating that there are no
significant structural changes in the folded prion domain upon
compound binding. However, the side chains of the residues
involved in the interaction with promazine show conformational
changes that accommodate the hydrophobic ligand inside the
binding pocket. In the bound structure, the side chain of
Gln186 shifts by 108 at the Cb position, accommodating a
hydrophobic contact with the convex face of the phenothiazine
ring (Figures 2A–2C). The side chains of Tyr128 and Lys185 rear-
range within the binding pocket and together contribute 60 A˚2
to the interaction surface (Figures 2A–2C). For free moPrP,
access to the binding site is restricted by the close side-chain
packing of Leu125 and Lys185 that reside on opposite sides of
the pocket; a gap of 5 A˚ is observed between the ε-amino groupStructure 22, 291–303, February 4, 2014of Lys185 and the Cd2 atom of the
aliphatic side chain of Leu125 (Figures
2B and 2C). In the bound conformations,
the Ca atoms of residues Gly124 and
Leu125 show a shift of4–5 A˚ that results
in a movement of Leu125 away from
Lys185, rendering the binding pocket
more accessible (Figures 2A–2C). In the
chlorpromazine bound structure, similar
main-chain and side-chain positional
shifts for Leu125 and Lys185 are
observed, however, to positions that are
intermediate between the conformations
observed for the free and promazinebound states (Figure 2C). The side chain of Gln186 exhibits a
conformational change in the promazine bound structure, but
not in the chlorpromazine bound state. We speculate that the
structure of the chlorpromazine complex may represent an inter-
mediate stage encountered while making its passage to the
binding pocket (Figure S2).
Phenothiazine Binding Induces the Formation of a
‘‘Hydrophobic Anchor’’ at Residues 119–124 of the
N-Terminal Region
The native prion protein has a structured domain comprising
three helices (a1, a2, and a3), two short antiparallel b strands
(b1 and b2), and a long, disordered N-terminal domain from
residues 23–124. The electron density for residues 119–124
becomes defined upon promazine binding (Figures 2D and S3).
This leads to a structural rearrangement at the N terminus of
the structured domain of moPrP (residues 117–124), through
the formation of an additional b strand that is antiparallel to b1;
this strand was previously shown to be flexible in the moPrP
NMR structures (Figure S3). These changes occur in the vicinity
of a second POM1 Fab:moPrP complex molecule; the proximity
of POM1 Fab possibly explains why the attempts at cocrystalli-
zation with phenothiazine compounds were not successful (Fig-
ures S2C and S2D). In the unbound POM1 Fab:moPrP crystal
structure, there is a narrow gap present around the b1-b2 region,ª2014 Elsevier Ltd All rights reserved 293
Figure 2. Structural Changes upon Binding
of Phenothiazine Derivatives
(A) Surface representation of moPrP (green) bound
to promazine with interacting residues shown as
sticks and promazine shown as a ball and stick
model with the carbon, nitrogen, and sulfur atoms
colored cyan, blue, and yellow, respectively.
(B) Surface representation of moPrP in the free
conformation (PDB ID: 4H88, violet).
(C) Superposition of bound and free moPrP
structures: moPrP:promazine in green, moPrP:
chlorpromazine in gray, and free moPrP in violet.
Residues in contact with the phenothiazine de-
rivatives are shown as sticks. Conformational
changes induced by phenothiazine binding are
indicated by arrows.
(D) The 2jFoj  jFcj electron density map for resi-
dues 119–128 is shown at 1swithmoPrP residues
(green) shown as sticks.
See also Figure S2.
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Anti-Prion Mechanism of Phenothiazine Compoundsbetween the two neighboring protein complexes and with no
contacts between the molecules. However, upon promazine
binding the additional beta strand is formed in this gap region
while making contacts with the adjacent protein complex. There
is only room for a few amino acids to be accommodated in this
region and therefore, the His-tag cleaved moPrP (120–230) and
moPrP (117–230) constructs produced the electron density for
the ligand as well as for the disordered moPrP region prior to
residue Leu125. However, in the absence of the compound,
this beta strand is not observed indicating that the formation of
the beta strand in the unstructured moPrP region (residues
117–124) is dependent on the compound binding. In this antipar-
allel b-arrangement, however, the previously unstructured N-ter-
minal region forms backbone hydrogen-bonded interactions
with strand b1; the main-chain amide and the carbonyl group
of Ala120 form hydrogen bonds with the main-chain carbonyl
and the amide group of Leu130, respectively (Figure 2D). Addi-
tionally, two tandem b-turns are observed in the unstructured
region of residues 119–124 upon promazine binding; a type I
b-turn is present between Val122–Leu125 and a type II b-turn
is present between Leu125–Tyr128 (Figure S3). However, in
the chlorpromazine bound structure, although the electron den-
sity for residues 119–124 is traceable, it is incomplete, hindering
the structural interpretation for this region.
The side chains from residues Tyr128-Met129-Leu130 (YML)
of strand b1 and Tyr162-Tyr163-Arg164 (YYR) of b2 are closely
packed together through systematic interstrand hydrophobic294 Structure 22, 291–303, February 4, 2014 ª2014 Elsevier Ltd All rights reservedpairing (Tyr128:Arg164, Met129:Tyr163,
and Leu130:Tyr162) both above and
below the plane of the short, antiparallel
b sheet (Figure 3B). In the presence of
promazine, we observe analogous hy-
drophobic interactions, in the unstruc-
tured region adjacent to the YML and
YYR motifs; the side chains of the resi-
dues belonging to the unstructured N
terminus, 119GAVVGGL125, and residues
from the b1-b2 region are engaged inhydrophobic interactions (Figure 3A). The side chain of Leu125
is packed against the side chain of Val122 from the b strand
formed in the bound state, thus creating a ‘‘hydrophobic anchor’’
at this region. In addition, the side chain of Val122 interacts with
the methyl group of the dimethylaminopropyl side chain of
promazine. On the other side of the hydrophobic anchor,
Leu125 is involved in hydrophobic interactions with the aromatic
side chains of Tyr128 andTyr162 locatedwithin 4–5 A˚ (Figure 3A).
Similarly, below the plane of the b sheet, the side chains of
Val121 and Met129 are within 4 A˚, forming hydrophobic con-
tacts. The formation of b sheet secondary structure in presence
of phenothiazine-like compounds is likely an essential character-
istic for the mechanism of PrPSc inhibition, as the hydrophobic
dimethylaminopropyl side chain induces the formation of a
well-defined structure within a disordered region of the prion
protein. Previous structure activity relationship studies on tricy-
clic acridine and phenothiazine compounds indicate that the
presence of long side chains attached to the central tricyclic
scaffold is a vital requirement for inhibition; the absence of this
feature, as in case of phenazine, phenothiazine, and 2-chlorphe-
nothiazine, results in abolition of therapeutic benefit (Korth et al.,
2001). The physicochemical nature of the side chain including
length, flexibility, and hydrophobicity are essential parameters
that can influence therapeutic outcomes, as rigid bonds at the
tricyclic N-atom are known to reduce therapeutic efficacy signif-
icantly. The long, flexible, and hydrophobic side chain covalently
attached to the acridine nitrogen of quinacrine is effective for
Figure 3. Formation of the Hydrophobic
Anchor at the N Terminus
(A) Hydrophobic surface of Val121, Val122, and
Leu125 shown in a space-filling models (pink)
contact residues from strand b1 (Tyr128, Met129,
and Leu130, space-filling model, blue) and strand
b2 (Tyr162, Tyr163, and Arg164 space-filling
model, orange).
(B) Hydrophobic interactions between residues
from strands b1 and b2 are shown as space-filling
models in blue and orange, respectively. Hydro-
phobic pairs Tyr128:Arg164 and Leu130:Tyr162
are formed above the b-plane, whereas Met129:
Tyr163 is formed below the plane.
See also Figure S3.
Structure
Anti-Prion Mechanism of Phenothiazine Compoundsstabilizing secondary structure within regions that are otherwise
disordered in the free state, whereas the tricyclic scaffold is
bound to the structured prion domain.
Phenothiazine Binding Stabilizes the b2-a2 loop through
a Hydrogen Bond Network
The residues within the b2-a2 loop are within 10 A˚ from the
binding pocket for phenothiazine compounds. Experimental
evidence implicates this loop region in initiating PrPSc conver-
sion and possibly influencing interspecies scrapie transmission
(Damberger et al., 2011; Sigurdson et al., 2011). We observe
that on binding to promazine, the side chain of Tyr128 from
strand b1 shows an inward movement of 45 (at Chi-2), and
Tyr128 forms a hydrogen bond between the hydroxyl group
and a carboxylate oxygen of Asp178, present in helix a2 (Fig-
ure 4A). This inward shift of Tyr128 makes the aromatic side
chain move 3 A˚ closer toward Ile182 in helix a2 thereby
increasing the hydrophobic contact surface. The native moPrP
NMR structures show multiple orientations for the b2-a2 loop,
under different experimental conditions (Figures 4C–4F). How-
ever, the additional interactions between the residues of strand
b1 and helix a2 in the presence of promazine influence the orien-
tation of the b2-a2 loop. Various structures of moPrP in the free
and bound states indicate that Tyr169 in the b2-a2 loop adopts
several different conformational positions, ranging from an out-
ward-facing solvent accessible orientation to a inward-facing,
fully buried position, with additional orientations intermediate
between open and buried (Figures 4A–4F), with concomitant
backbone isoforms within this flexible region are also seen.
The relative positions for the polar residues Arg164, Asp167,
and Gln168 in the b2-a2 loop also change depending on theStructure 22, 291–303, February 4, 2014loop backbone conformation. In the
promazine bound structure, a cation-pi
interaction is observed between the side
chains of Arg164 and Tyr128 residues;
they are separated by 4 A˚ apart (Fig-
ure 4A). These side chain orientations
appear to be an essential feature that
could provide a stabilizing effect on the
b1-b2 sheet as well as on the b2-a2
loop region. However, in the absence of
ligand, Arg164 and Tyr128 are separated
by 4.8 A˚, disrupting the potentially stabi-lizing cation-pi interaction between these side chains (Figure 4B).
Additionally, in the bound state, the hydrogen bonding inter-
action between Tyr128 and Asp178 stabilizes a side chain
conformation of Asp178 that is suitable for Tyr169 to make a
hydrogen bonding interaction with the carboxylate oxygen of
Asp178 (Figure 4A). For the promazine bound structure, there
are two hydrogen bonding interactions for Asp178, these involve
Tyr128 and Tyr169. In the unbound moPrP structures, either a
single or no hydrogen bond is observed (Figures 4B–4F).
Although the bound and free states exhibit identical b2-a2 loop
conformations, the bound state of the b2-a2 loop appears
more stable and has additional interactions with Tyr128 that
most likely prevent an easy transitioning of the Tyr169 side chain
conformation.
PhenothiazineBinding Stabilizes the a2-a3Hydrophobic
Core through Allosteric Interactions
The binding of promazine to 15N-labeled shPrP(90–232) in solu-
tion was investigated using heteronuclear NMR spectroscopy.
Chemical shift changes for the main chain amides of PrP upon
titration of promazine to shPrP(90–232), were analyzed (Figures
5A and S4A). Most of the residues displaying significant chemi-
cal shift changes on binding to promazine were found to cluster
into two separate regions of the prion protein. The first region is
the a2-a3 loop and the neighboring residues in helices a2 and
a3. The second region is helix a1, specifically those residues in
contact with a3. Among these two clusters, helix a2 is nearest
to the promazine binding site, and Thr188 within a2 shows the
largest chemical shift deviation upon promazine binding. Resi-
dues neighboring Thr188 such as Phe198 in the a2-a3 loop,
and Val203, Met206, and Val210 in helix a3 also show chemicalª2014 Elsevier Ltd All rights reserved 295
Figure 4. Conformational Heterogeneity at b2-a2 Loop Region
Side chains of selected residues are represented as sticks, with hydrogen bonds shown as dashed lines.
(A) In the moPrP:promazine crystal structure (green), Tyr128, Asp178, and Tyr169 form a hydrogen bonded network.
(B) In the moPrP crystal structure (PDB ID: 4H88, violet), Tyr128 lacks a hydrogen bond to Asp178.
(C) In the moPrP NMR structure (PDB ID: 1XYX, purple), Tyr128 is hydrogen bonded to Asp178, and Tyr169 is fully buried.
(D) In the moPrP NMR structure (PDB ID: 2L39, blue) Tyr128 is hydrogen bonded with Asp178, Tyr169 is partially buried, with an altered loop conformation.
(E) In the moPrP NMR structure (PDB ID: 2L1H, orange) there are no hydrogen bonding interactions between Tyr128, Tyr169, and Asp178.
(F) In the moPrP NMR structure (PDB ID: 1AG2, wheat), hydrogen bonds are present between Tyr128:Asp178 and Asp178:Arg164, and Tyr169 is completely
surface-exposed.
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Anti-Prion Mechanism of Phenothiazine Compoundsshifts changes for the backbone amides (Figure S5B). As the
residues of the a2-a3 loop and the a3 helix are in contact with
those of helix a1, small chemical shift changes are observed
for some residues in a1. Thus, chemical shift changes are in
agreement with the crystallographically determined structures
for the promazine bound state. Addition of promazine to
12 mM (Figure S4A) produces a pattern of chemical shift
changes similar to the addition of 6 mM, however, further
increasing promazine concentration leads to protein aggrega-
tion. We observed linear changes in the chemical shifts upon
addition of promazine that seems to indicate weak binding
with shPrP. Furthermore, we observe chemical shift perturba-
tions for residues distal from the promazine binding site; these
changes reflect subtle structural changes that are transmitted
through the various secondary elements of PrP upon ligand
binding. Formation of the additional beta strand at the N-terminal
region as seen in the crystal structure of POM1 Fab:moPrP:
promazine could not be confirmed by NMR spectroscopy due
to the lack of back bone resonance assignment for the residues
119–124 in shPrP. However, it is noteworthy that despite the
use of two different systems—moPrP with POM1 Fab in X-ray
crystallography and shPrP without POM1 Fab in NMR spectros-296 Structure 22, 291–303, February 4, 2014 ª2014 Elsevier Ltd All rcopy—we obtained similar promazine binding results. Hence,
we conclude that the promazine binding to the moPrP in the
crystal structure of POM1 Fab:moPrP:promazine is not influ-
enced by POM1 Fab binding.
Promazine Binding Attenuates PrP Flexibility
To assess the role of changes in protein dynamics upon drug
binding, we conducted molecular dynamic (MD) simulations
using the structured domain from moPrP (residues 119–225) in
the presence and in the absence of promazine. Free moPrP
shows flexibility within the a2-a3 loop and the adjoining residues
in helices a2 and a3 (Figure 6B). Per residue root-mean-square
fluctuation (rmsf) values indicate a flexible region within the
C-terminal half of the domain, near the end of helix a2
(190TTTTK194). Large amplitude B-factors for atoms from the C
terminus of helix a2 and the a2-a3 loop in various PrP X-ray
structures (Figure S5A), and the different conformations
observed in the NMR structural ensembles (Figure S3A), are
consistent with the flexibility of these regions observed in the
MD simulation. The C-terminal unwinding of the a2 helix may
result from the consecutive Thr residues involvement in polar
interactions with main-chain atoms of the a2-a3 loop. The lossights reserved
Figure 5. Stabilization of the Hydrophobic
Core through Allosteric Interactions
(A) Overlay of the 2D 1H-15N HSQC NMR spectra
of shPrP90–232 in the absence (black) and pres-
ence of 6 mM (cyan) and 12 mM (red) promazine.
(B) The inset shows individual residues having
significant chemical shifts changes.
(C) The heat map showing residues from shPrP for
which backbone amide resonances are attenu-
ated by the addition of promazine, with red broad
ribbons indicating maximum perturbation.
See also Figure S4.
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Anti-Prion Mechanism of Phenothiazine Compoundsof helical structure at the C terminus of a2 perturbs the hydro-
phobic core network maintained by side chain interactions at
the interface of the a2-a3 hairpin structure (Figures 6D, S5C,
and S5D). Upon promazine binding, there is a significant reduc-
tion in the rmsf of the residues proximal to the binding site, for
which Thr190 is involved in key interactions with promazine.
During the time course of the simulation, the tricylic compound
was found to contact Ile182, Lys185, Gln186, and Val189 in
a2. Interestingly, the secondary structure over the course of
the simulation (Figures 6A, S5C, and S5D), indicates that the
helical content of a2 remains stable on binding promazine, likely
as a result of close hydrophobic interactions between the pro-
mazine and moPrP. Recent long timescale simulations (1 ms)
for ovPrP (sheep prion) indicate that loss of the C-terminal helical
structure for helix a2 is a critical step in the conversion of PrPC
into the b-rich conformer (Chakroun et al., 2013).
DISCUSSION
Despite tremendous progress in the field of prion biology, the
molecular events responsible for PrPSc formation from cellular
prion protein remain elusive. There is general consensus
regarding the posttranslational, multistep refolding processes,
in which the native PrPC undergoes themalicious conformational
changes leading to the assembly of b sheet-rich, protease-resis-
tant PrPSc molecular aggregates. Once formed, PrPSc recruits
partially folded, nonnative intermediates, a process that leads
to formation of long fibrillar structures, as observed through
many biophysical techniques (Caughey et al., 2009). Although
there is ample evidence suggesting the existence of aberrant
prion intermediates, the precise involvement for the various
secondary structural elements of PrPC in amyloid formation is
unknown.Structure 22, 291–303, February 4, 2014Promazine and chlorpromazine binding
to prion protein induced the formation
of a hydrophobic anchor between the
N-terminal segment comprising Gly119–
Gly124 and residues from b1 (Figure 3A
and Table 2). The unstructuredN-terminal
part of the prion protein adjacent to the
structured domain is responsible for prion
toxicity; specifically, residues 106–126
from the mammalian prion protein (Et-
taiche et al., 2000; Forloni et al., 1993).
This segment has been extensivelystudied both as a neurotoxic amyloid prion and as a potential
mediator for the conversion of PrPC to the scrapie form (Forloni
et al., 1993; Jobling et al., 1999; Salmona et al., 1999; Selvaggini
et al., 1993). The conserved palindromic sequence
113AGAAAAGA120 within residues 106–126 has been implicated
in the assembly of amyloid fibrils and neurotoxicity (Jobling
et al., 1999; Lee et al., 2008). Solid state NMR structural data
for PrPC 106–126 peptide fibrils suggest the formation of a
class-1 steric zipper motif constituting Gly114-Gly123, is
involved in an extensive, interdigitated interface between two
parallel beta sheets (Walsh et al., 2009). Given that this flexible,
unstructured region of PrPC exhibits a tendency to self-aggre-
gate, binding of small molecules to this region may reduce the
flexibility and facilitate formation of secondary structure, thereby
providing a potential path to therapeutic intervention. Interest-
ingly, the secondary structure induced by promazine and
chlorpromazine binding results in the burial of Met129 from
strand b1. This residue has been implicated in conformational
selection of prion strains and confers susceptibility to prion
diseases through the common human methionine-valine poly-
morphism at PRPN codon 129 (Collinge et al., 1996; Lewis
et al., 2006; Wadsworth et al., 2004). Although Met129 polymor-
phism does not involve altering the native structure or the global
stability of PrP (Hosszu et al., 2004), structural data on prion
proteins suggest that an intermolecular four-stranded sheet
formation from two adjacent prion protein molecules at strand
b1 is possibly a crucial event in the transition to PrPSc (Figure S6)
(Antonyuk et al., 2009; Lee et al., 2010). Sawaya et al. (2007)
experimentally demonstrated that the formation and propaga-
tion of cross-b amyloid spines are essentially reliant on the pri-
mary stacking event of antiparallel beta strands, as observed
in the PrP structures. Phenothiazine-induced formation of addi-
tional secondary structural elements may deter PrP stacking atª2014 Elsevier Ltd All rights reserved 297
Figure 6. Promazine Acts as an Attenuator of Flexibility
(A and B) Time-dependence for the secondary structure of moPrP (A), in the presence and (B), in the absence of promazine during MD simulations, respectively.
(C) Rmsf for themoPrP protein duringMD simulations in the presence (pink) and in the absence of promazine (blue). Alpha helices and b strands are shown in blue
and yellow, respectively, promazine binding residues are indicated by green lines.
(D) Ribbon representation for the backbone atoms of moPrP in the unbound state, backbone rmsf values are represented by the width of the ribbon and colored
according to the magnitude of atomic fluctuations.
See also Figure S5.
Structure
Anti-Prion Mechanism of Phenothiazine Compoundsstrand b1, particularly in the vicinity of Met129, and arrest the
toxic consequences of oligomer formation.
It has been suggested that PrP subdomains b1-a1-b2 and a2-
a3 must be separated in order to promote PrPSc formation, as
chemical tethering of these subdomains through the introduction
of disulfide bridges prevents toxic conversion (Hafner-Bratkovic
et al., 2011). In the promazine bound structure of moPrP, we
observe an analogous tethering of these subdomains; the b1-
a1-b2 motif, with the help of the hydrophobic anchor prior to
strand b1, attaches strongly to helix a2, with the hydrophobic
tricyclic phenothiazine scaffold present at the interface (Fig-
ure 3A). In addition, the binding of promazine leads to burial of
the YYR motif in strand b2; this motif was previously shown to
be preferentially exposed in PrPSc, in the denatured form of
PrPC, but not in the cellular isoform, PrPC (Paramithiotis et al.,
2003). Furthermore, it has been demonstrated that a primary
step in the urea induced denaturation of PrPC involves unfolding
of the native b sheet (Julien et al., 2009). The phenothiazine mol-
ecules bound to PrPC provide additional stability to this b sheet
region as they bind to PrPC at a critical site, where residues
from both strands b1 and b2 are able to contact the tricyclic ring.
Recently, the b2-a2 loop region of the prion protein has
attracted intense interest with respect to its potential role in298 Structure 22, 291–303, February 4, 2014 ª2014 Elsevier Ltd All rthe onset of TSEs (Christen et al., 2013). Specific residues
in this labile region, between positions 167 and 170 have been
shown to increase susceptibility to interspecies prion trans-
mission, as well as leading to spontaneous PrPSc generation
in transgenic mice (Agrimi et al., 2008). Structural studies
indicate surface polymorphism of this region due to the ‘‘in’’
and ‘‘out’’ conformational transitioning of residue Tyr169
(Christen et al., 2013). The solvent-exposed out conformation
leads to increased hydrophobicity in the loop structure and
has been linked to cytotoxicity (Corsaro et al., 2011). The b2-
a2 loop has two known distinct backbone conformations, a
310-helix, seen in the majority of the PrP
C structures, and
an aberrant type-I b-turn structure, seen in a few PrPC con-
formations, that may increase the propensity for transitioning
to PrPSc. In both the bound and unbound forms of moPrP struc-
tures, the b2-a2 loop acquires a 310-helix conformation with
Tyr169 having an in conformation. However, in the presence of
promazine, an additional hydrogen bond network is formed
between residues Tyr128, Tyr169, and Asp178, that stabilizes
the b2-a2 loop. On this basis, we propose that the Asp178
to Asn mutation, as found in FFI, destabilizes the b2-a2 loop
giving rise to a type-I b-turn conformation due to disruption of
the hydrogen bond network.ights reserved
Table 2. Backbone 4 and c Torsian Angles Measured for the N
Terminus Region, Residues 119–129 of moPrP
Residue Number Amino Acids F () J ()
119 GLY — 151.1
120 ALA 100.0 140.2
121 VAL 114.9 136.0
122 VAL 140.1 170.9
123 GLY 9.3 112.4
124 GLY 124.2 79.0
125 LEU 92.2 4.3
126 GLY 54.4 48.2
127 GLY 95.7 21.8
128 TYR 79.4 156.8
129 MET 129.5 153.6
Structure
Anti-Prion Mechanism of Phenothiazine CompoundsSeveral mutations in the structured domain of prion protein
that have been implicated in the conversion to the scrapie form
significantly affect the thermodynamics and stability of PrPSc
(van der Kamp and Daggett, 2010). An extensive hydrophobic
network between helical secondary structures in the folded
domain forms the hydrophobic core of the prion protein. The
pathogenic mutations V180I (CJD), F198S (GSS), V203I (CJD),
and V210I (CJD), are found at the interface of helices a2 and
a3 (Figure S5B); these mutations significantly alter the dynamic
equilibrium between folded and unfolded states of the hydro-
phobic core, leading to the PrPSc formation (Apetri et al.,
2004). Molecular dynamics simulations for ten disease-associ-
ated mutations in PrP show significant structural perturbations
at the a2-a3 hairpin interface, themajor component of the hydro-
phobic core (Meli et al., 2011). Our NMR chemical shift data
indicate that promazine binding perturbs the interface between
helices a2-a3, supporting the idea that promazine binding may
allosterically enhance the packing between the helices. Consis-
tent with the NMR experiments, the molecular dynamics simula-
tions we conducted show that promazine binding attenuates the
flexibility of the C-terminal region of helix a2, thereby facilitating
more extensive interhelical packing. This flexible prion region,
the C-terminal part of helix a2 and the a2-a3 loop, is the recog-
nition site for antiprion compound GN8, a small molecule that
prolongs the survival of TSE-infected mice (Kuwata et al.,
2007). The promazine binding site is adjacent to that of GN8,
and the overlapping epitope regions for these molecules on
the prion protein share Val189, a residue which forms part of
the C terminus of helix a2.
We have demonstrated that phenothiazine derivatives facili-
tate the prevention of PrP misfolding thorough a multifaceted
protein stabilization mechanism. Promazine elicits a chap-
erone-like effect at three noncontiguous toxic motifs of the
PrPC molecule: the antiparallel b1-b2 region, b2-a2 loop, and
the C-terminal part of helix a2. In addition to the stabilizing effect
on various PrPC motifs, burial of both the aggregation prone
N-terminal flexible region and Met129 are essential to the stabi-
lization mechanism of this antiprion compound. Formation of
the scrapie form of the prion protein fromcellular PrPmay involve
concerted structural perturbations in different motifs of the
folded domain, coupled to preferential exposure of the aggrega-Structure 22, 29tion prone prion region, which subsequently interacts with
contagious agents. This is evident from the diverse natures
of the extrinsic and intrinsic factors that are responsible for initi-
ating the pathological conversion process of prion protein to the
scrapie form. A key step in the conversion likely involves prion
misfolding, initiated by individual toxic motifs separately or in
combination (Figure 7). These intermediate states for PrPC
have been recognized to lead to aberrant self-assembly.
Our structural data for small-molecule binding to the prion
protein uncovers the phenothiazine recognition site on the prion
protein and illuminates the allosteric mechanism by which sta-
bility is imparted to misfolding-prone regions. The antimalarial,
tricyclic acridine derivative quinacrine, failed to produce a favor-
able outcome in clinical trials involving CJD patients (Collinge
et al., 2009; Geschwind et al., 2013), despite promising results
in cell-culture models (Korth et al., 2001). This discrepancy
between in vitro and in vivo studies, whether related to phar-
macokinetic and/or pharmacodynamic properties of quinacrine,
is a matter of further investigation. However, the emergence of
a drug resistant strain of PrPSc due to the continuous treatment
of PrP diseases with quinacrine (Ghaemmaghami et al., 2009)
perhaps indicates a shifting of the misfolding center to other
motifs that are not stabilized by quinacrine. This behavior of
the prion protein supports the idea of a multi-focal nature for
the initiation of misfolding. In this scenario, we propose that
multiple antiprion drugs with unrelated molecular mechanisms
of action may be administered in a simultaneous fashion to elicit
a cumulative and more beneficial effect. Our high-resolution
structural data will be very useful toward enhancing the thera-
peutic potential of tricyclic compounds through a structure-
guided approach.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of moPrP(117–230)
The expression vector pET15b (Novagen) was used for the expression of the
mouse PrP(117–230). For cloning, two primers flanking the PrP117–230 region
of the full-length mouse Prion protein were designed with the BamH1 and
EcoR1 restriction sites, respectively. Upon PCR amplification, this insert was
incorporated into the multiple cloning site of pET15b vector between the
BamH1 and EcoR1 restriction sites. The fidelity of the cloned gene was
validated by sequencing. Upon confirming the sequence, the plasmid was
transformed into BL21-CodonPlus (DE3)-RIL cells (Stratagene) by heat-shock.
The cells were grown in Luria-Bertani (LB) broth containing 0.1 mg/ml ampi-
cillin and 0.34 mg/ml chloramphenicol at 37C, 200 rpm, and the PrP(117–
230) expression was induced in the inclusion bodies using 0.1 M isopropyl
b-D-1-thiogalactopyranoside (IPTG). The inclusion bodies were sonicated,
pelleted by centrifugation, and extensively washed. Subsequently, the inclu-
sion bodies were incubated in a denaturing buffer G of 8 M Urea, 10 mM
Tris-HCl, 100 mM NaH2PO4, and 5 mM reduced glutathione pH 8.0 for 1 hr
at room temperature with constant stirring. The extracted denatured
PrP(117–230) was purified using metal affinity chromatography by loading
onto a Ni-NTA agarose column (QIAGEN). The bound PrP(117–231) was re-
folded on-column by gradient application of buffer G (denaturing buffer) to
buffer A (10 mM Tris-HCl, 100 mM NaH2PO4, 5 mM imidazole, pH 8.0) as
described by Yin et al. (2003). After the refolding, the nonspecifically bound
impurities were removed by washing with 10 mM Tris-HCl, 100 mM NaH2PO4,
50 mM imidazole, pH 8.0. Finally, the pure PrP(117–230) was eluted with the
elution buffer containing 10 mM Tris-HCl, 100 mM NaH2PO4, 400 mM imid-
azole pH 5.8. The obtained protein was exchanged into distilled water using
Amicon Ultra centrifugal filters (3 kDa molecular weight cutoff; Millipore). The
purity was confirmed by SDS-PAGE and the concentration was determined
by the Bradford method (Bradford, 1976).1–303, February 4, 2014 ª2014 Elsevier Ltd All rights reserved 299
Figure 7. Initiator Motifs in Prion
Several misfolding initiator motifs are observed in
the structured domain of prion protein. These
include exposure at Met129, separation of b1-b2,
unfolding of prion subdomains; b1-a1-b2 and a2-
a3, alternate conformation of b2-a2 loop, flexibility
at a2-a3 loop, and hydrophobic core destabiliza-
tion between a2-a3. Generation of PrPSc can be
possible due to lethal progression involving indi-
vidual or multiple toxic motifs.
See also Figure S6.
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Anti-Prion Mechanism of Phenothiazine CompoundsExpression and Purification of [U–15N] shPrP(90–232)
The shPrP90–232 construct cloned into a pET15b expression vector was
obtained from PrP5. The plasmid was transformed into BL21-CodonPlus
(DE3)-RIL cells (Stratagene) by heat-shock, and an isolated colony was grown
overnight in 50 ml of LB broth. This starter culture was inoculated (in a 1:100
ratio) into 1 l of M9 media with 1 g/l of unlabeled NH4Cl at 37
C with shaking
at 200 rpm. The cells were allowed to reach an OD of 0.6, after which they
were exchanged into M9 media with 1 g/l of 15N-ammonium sulfate and
induced with 1 mM IPTG. The induced culture was allowed to grow for 16–
18 hr at 37Cwith shaking at 200 rpm. The cells were then harvested by centri-
fugation at 8,000 rpm for 30 min at 4C. Further extraction and purification of
the protein was performed as described above. The protein was stored in
buffer containing 10 mM BIS-TRIS, 100 mM Na2HPO4, pH 5.8.
Production and Purification of POM1 Fab
The POM1 hybridoma was generated as described previously (Polymenidou
et al., 2008). In order to purify secreted IgG, the hybridoma supernatant was
loaded on to a protein G Sepharose column (PIERCE) and eluted with 0.1 M
glycine, pH 2.8. For production of POM1 Fab, 1 mg/ml of POM1 IgG was
digested with papain at an IgG:papain ratio of 1:0.02 (w/w) in buffer containing
50 mM TRIS, 150 mM NaCl, 2 mM EDTA, and 2 mM cysteine, pH 8, for 5 hr at
37C in a water bath. Enzymatic digestion was terminated by addition of 3 mM
iodoacetamide. The digest was subsequently concentrated and buffer
exchanged with protein A binding buffer (PIERCE) and loaded onto a protein
A Sepharose column (Pierce) to remove the Fc fragment and undigested IgG
POM1. The purified POM1 Fab fragment was directly collected in the flow-
through. The Fab fractions were assessed for homogeneity by Coomassie bril-
liant blue staining after separation by SDS-PAGE.
Protein Complex Preparation, Crystallization, and Soaking
The POM1 Fab and the purified moPrP (residues 117–230) were mixed in an
equimolar ratio and the resulting complex was purified by size exclusion chro-
matography using a Superdex G-75 column (Amersham Biosciences). The
chromatography buffer contained 50 mM TRIS, 100 mM NaCl, and 1 mM
NaN3, pH 7. For the purposes of crystallization, the purified protein complex
was concentrated to 10 mg/ml. High-throughput crystal trays (96-well Intelli-
Plates, Hampton Research) were set up by the sitting drop vapor-diffusion
method using a robot (Hydra 96 plus one, Robbins Scientific), in which 0.4 ml
of the protein sample was mixed with an equal volume of the screening solu-
tion. An initial crystallization hit was found in a saturating solution of 25%
PEG3350, 0.1 MMES pH 6.5, and 0.1 M lithium sulfate. After several optimiza-
tion steps, crystals with approximate dimensions of 0.6 3 0.1 3 0.1 mm were300 Structure 22, 291–303, February 4, 2014 ª2014 Elsevier Ltd All rights reservedobtained within 7 days. These crystals were
soaked briefly for 1–2 min in solution containing
1–10 mM concentrations of phenothiazine deriva-
tives. The selected crystals were then flash frozen
in liquid nitrogen after the addition of 20%ethylene
glycol as a cryoprotectant.
Data Collection, Structure Determination,
and Refinement
Full data sets from the small molecule soaked
crystals of the POM1 Fab:moPrP(117–230) com-plex were collected at beamline 9-2 of the Stanford Synchrotron Radiation
Lightsource (SSRL) and at the beamline 19ID at the Advanced Photon Source
(APS). The measured data were processed with the HKL2000 suite of
programs (Otwinowski and Minor, 1997), and data collection statistics are
presented in Table 1. The structure of the complex was solved by the molec-
ular replacement method using the programMOLREP from the CCP4 package
(Winn et al., 2011), using the structure of POM1 Fab (PDB ID: 4H88) as a search
model. The obtainedmodels of the POM1 Fab:moPrP(117–230) complex were
then refined using the Refmac package (Murshudov et al., 2011). After the
initial rounds of refinement, clear density for the ligands was visible in the
difference electron density maps (2jFoj  jFcj). The promazine and chlorprom-
azine ligand molecules were built using the program PRODRG from the CCP4
suite (Winn et al., 2011) and fit into the difference electron density map of the
complex using the program COOT (Emsley and Cowtan, 2004). The progress
of the refinement process wasmonitored by the reduction in theRwork andRfree
factors. Solvent molecules were added to the model by manual inspection and
only those water molecules with well-defined positive peaks in both the 2jFoj 
jFcj and jFoj  jFcj electron density maps, and satisfactory hydrogen bond
networks with either protein atoms or water molecules were accepted. All of
the model building was performed with COOT (Emsley and Cowtan, 2004).
The final coordinates of the POM1 Fab:moPrP(117–230) complexes bound
with promazine and chlorpromazine have been deposited in the Research
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank with
the PDB ID 4MA7 for the promazine complex and 4MA8 for the chlorpromazine
complex. The residue numbering scheme of huPrPwas used formoPrP in both
the complexes.
NMR Sample Preparation and Data Recording
All the NMR experiments were acquired at 25C on a 600 MHz Varian Unity
INOVA spectrometer with a 5 mm HCN probe with triple-axis pulsed field
gradients and the Varian BioPack Pulse sequence library. All spectra acquired
were processed using NMRPIPE (Delaglio et al., 1995) and analyzed with
CARA (Keller, 2004) and SPARKY (Goddard and Kneller, University of
California, San Francisco; http://www.cgl.ucsf.edu/home/sparky). The 2D
15N-HSQC NMR experiments were acquired using 1,126 complex points
over a spectral width of 8,800.88 Hz in the direct dimension (1H) and 128 com-
plex points over a spectral width of 1,882 Hz in the indirect dimension (15N).
Sixteen transients were collected for all 2D experiments using a recycle delay
of 1.5 s. 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) was used for chemical
shift referencing. For titration experiments with promazine, a reference 2D
15N-HSQC spectrumwas collected using 500 mMshPrP(90–232) in buffer con-
taining 9:1 H2O:D2O, 20 mM KH2PO4, pH 6.2. Subsequently, 2D
15N-HSQC
Structure
Anti-Prion Mechanism of Phenothiazine CompoundsNMR spectra were acquired by addition of promazine to concentrations of 0.5,
1, 6, and 12 mM. Chemical shifts were assigned according to those in deposi-
tion Biological Magnetic Resonance Data Bank (BMRB) 17834.
MD Simulations
MD simulations were conducted for 20 ns using the Sander module and the
ff12SB force field in the AMBER 12 package (Salomon-Ferrer et al., 2013).
The starting structural model for moPrP(119–225) bound to promazine was
taken from the crystal structure of POM1 Fab:moPrP:promazine (PDB ID:
4MA7). For the unbound moPrP(119–225) starting structure, promazine mole-
cule was removed. Force field parameters for the promazine molecule were
generated using am1bcc semi-empirical quantum mechanical methods, as
implemented in the program antechamber (Wang et al., 2006). The bound
and free moPrP(119–225) proteins were placed in a rectangular box filled
with TIP3P water molecules. The rectangular box was placed at a distance
of 10 A˚ from the protein surface. One sodium ion was placed in the vicinity
of the negatively charged residue at the protein surface in order to neutralize
the system. Prior to MD simulation, the protein geometry was optimized in
two stages with different constraints. In the first stage (1,500 steps), only water
molecules were relaxed, while the protein and the ligand molecule were
constrained using a harmonic potential with a force constant of 20 kcal/
(mol A˚2). For the second minimization stage (2,500 steps), no constraints
were employed; protein and solvent were minimized together. The above
geometry-optimized system consisting of 17,661 atoms was simulated using
periodic boundary conditions. The particle-mesh Ewald method (Darden
et al., 1993) was used to calculate the electrostatics interactions with a
nonbonded interaction cut-off of 12 A˚. During the first part of the equilibration
(100 ps of heating from 0 to 310 K), the NVT ensemble was used, while all the
subsequent simulations were carried out at constant temperature and pres-
sure (310 K and 1 atm, NPT ensemble). Bond lengths involving hydrogen
were constrained with the SHAKE algorithm (Lippert et al., 2007), and the
time step for all MD simulation was set to 2 fs.
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